Literature DB >> 15940282

Adopting an orphan.

Andrea Rinaldi.   

Abstract

Mesh：

Year:  2005        PMID： 15940282      PMCID： PMC1369105          DOI： 10.1038/sj.embor.7400450

Source DB:  PubMed          Journal:  EMBO Rep        ISSN： 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  3 in total

1.  The orphan drug backlash.

Authors:  Thomas Maeder
Journal:  Sci Am       Date:  2003-05       Impact factor: 2.142

Review 2.  Two decades of orphan product development.

Authors:  Marlene E Haffner; Janet Whitley; Marie Moses
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

3.  Rare essentials: drugs for rare diseases as essential medicines.

Authors:  Pieter Stolk; Marjolein J C Willemen; Hubert G M Leufkens
Journal:  Bull World Health Organ       Date:  2006-09       Impact factor: 9.408
  3 in total
  16 in total

1.  Policy alternatives for treatments for rare diseases.

Authors:  Abbas H Panju; Chaim M Bell
Journal:  CMAJ       Date:  2010-07-12       Impact factor: 8.262

2.  Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.

Authors:  Carl Rudolf Blankart; Tom Stargardt; Jonas Schreyögg
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

3.  Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.

Authors:  James W Dear; Pajaree Lilitkarntakul; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

4.  Orphan drugs for rare diseases: is it time to revisit their special market access status?

Authors:  Steven Simoens; David Cassiman; Marc Dooms; Eline Picavet
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

5.  Study and analysis of the state of rare disease research in Shandong Province, China.

Authors:  Heng Zhao; Yazhou Cui; Xiaoyan Zhou; Jingxiang Pang; Xiumei Zhang; Shuangqing Xu; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2012-11

Review 6.  Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives.

Authors:  Peipei Song; Jianjun Gao; Yoshinori Inagaki; Norihiro Kokudo; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2012-02

Review 7.  Orphan drug development: the increasing role of clinical pharmacology.

Authors:  Mariam A Ahmed; Malek Okour; Richard Brundage; Reena V Kartha
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-07-23       Impact factor: 2.745

8.  The definition of rare disease in China and its prospects.

Authors:  Yanqin Lu; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2022-02

9.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

10.  Pricing and reimbursement of orphan drugs: the need for more transparency.

Authors:  Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2011-06-17       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.